Shkreli backtracks on Daraprim pricing

Turing Pharmaceuticals AG (New York, N.Y.) CEO Martin Shkreli told media outlets on Tuesday his company will lower the price of Daraprim pyrimethamine. Shkreli told ABC TV that Turing would lower Daraprim's price "to allow the company to make a profit, but a very small profit." He also told NBC TV that Turing would lower the price to a level where the company will "break even or make a small profit."

Earlier in the day, Turing had issued a statement that the company intends to develop next-generation treatments for toxoplasmosis, invest in disease education and diagnosis, and provide financial assistance programs for the drug. The company declined to discuss pricing changes with BioCentury. ...